{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:12:25Z","timestamp":1790017945269,"version":"4.0.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1998,5]]},"DOI":"10.1212\/wnl.50.5.1222","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:33:32Z","timestamp":1336916012000},"page":"1222-1230","source":"Crossref","is-referenced-by-count":204,"title":["Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease"],"prefix":"10.1212","volume":"50","author":[{"given":"John C.","family":"Morris","sequence":"first","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"Cyrus","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Orazem","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Mas","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bieber","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca B.","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gulanski","sequence":"additional","affiliation":[{"name":"From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","unstructured":"Cummings JL Benson DF. Dementia: a clinical approach 2nd ed. Boston: Heinemann-Butterworth 1992."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.12_Suppl_8.S7"},{"key":"e_1_3_1_4_2","first-page":"4","volume":"76","year":"1987","unstructured":"Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-479.","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_3_1_5_2","first-page":"2","volume":"262","year":"1989","unstructured":"Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556.","journal-title":"JAMA"},{"key":"e_1_3_1_6_2","first-page":"1","volume":"2","year":"1976","unstructured":"Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.","journal-title":"Lancet"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410100102"},{"key":"e_1_3_1_8_2","first-page":"1","volume":"1","year":"1977","unstructured":"Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189-191.","journal-title":"Lancet"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6129.1"},{"key":"e_1_3_1_10_2","first-page":"1","volume":"30","year":"1974","unstructured":"Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-121.","journal-title":"A relationship to aging? Arch Neurol"},{"key":"e_1_3_1_11_2","first-page":"2","volume":"268","year":"1992","unstructured":"Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.","journal-title":"JAMA"},{"key":"e_1_3_1_12_2","first-page":"9","volume":"271","year":"1994","unstructured":"Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.","journal-title":"JAMA"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.1"},{"key":"e_1_3_1_14_2","unstructured":"Galasko DR Thal LJ. Cholinomimetic agents. In: Cummings JL Miller BL eds. Alzheimer's disease. Treatment and long-term management. New York: Marcel Dekker 1990:23-36."},{"key":"e_1_3_1_15_2","first-page":"4","volume":"54","year":"1997","unstructured":"Bodick NC, Offen WW, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_16_2","first-page":"5","volume":"11","year":"1962","unstructured":"Cerf J, Lebrun A, Dierichx J. A new approach to helminthiasis control: the use of an organophosphorus compound. Am J Trop Med Hyg 1962;11:514-517.","journal-title":"Am J Trop Med Hyg"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00351766"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00351766"},{"key":"e_1_3_1_19_2","first-page":"3","volume":"21","year":"1996","unstructured":"Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996;21:331-337.","journal-title":"Neurochem Res"},{"key":"e_1_3_1_20_2","first-page":"3","volume":"21","year":"1996","unstructured":"Hinz VC, Grewig S, Schmidt BH. Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996;21:339-345.","journal-title":"Neurochem Res"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Schmidt BH Hinz VC Blokland A van der Staay F-J Fanelli R. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker R Giacobini E Robert P eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkh\u00e4user 1996:217-221.","DOI":"10.1007\/978-1-4612-4116-4_32"},{"key":"e_1_3_1_22_2","unstructured":"Taylor P. Anticholinesterase agents. In: Hardman JG Limbird LE Molinoff PB Ruddon RW Gilman AG eds. Goodman and Gilman's the pharmacologic basis of therapeutics 9th ed. New York: McGraw-Hill 1996:161-176."},{"key":"e_1_3_1_23_2","first-page":"4","volume":"19","year":"1990","unstructured":"Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434.","journal-title":"Drug Dev Res"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.1.1"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Cummings JL Cyrus P Bieber F et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50.","DOI":"10.1212\/WNL.50.5.1214"},{"key":"e_1_3_1_26_2","first-page":"3","volume":"34","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:39-44.","journal-title":"Neurology"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90017-5"},{"key":"e_1_3_1_28_2","first-page":"4","volume":"7","year":"1980","unstructured":"Rosen WG, Terry RD, Fuld P, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_29_2","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th edition revised. Washington DC: American Psychiatric Association 1994."},{"key":"e_1_3_1_30_2","unstructured":"Leber P. Guidelines for the clinical evaluation of antidementia drugs. Washington DC: Food and Drug Administration 1990."},{"key":"e_1_3_1_31_2","first-page":"2","volume":"44","year":"1994","unstructured":"Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.","journal-title":"Neurology"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_3_1_33_2","unstructured":"Rockwood K Morris JC. Global staging measures in dementia. In: Gauthier S ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz Limited 1996:141-153."},{"key":"e_1_3_1_34_2","first-page":"2","volume":"44","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.","journal-title":"Neurology"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.139.1.1"},{"key":"e_1_3_1_36_2","first-page":"6","volume":"6","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.","journal-title":"Scand J Stat"},{"key":"e_1_3_1_37_2","first-page":"5","volume":"41","year":"1993","unstructured":"Aronson MK, Post DC, Guastadisegni P. Dementia, agitation and care in the nursing home. J Am Geriatr Soc 1993;41:507-512.","journal-title":"J Am Geriatr Soc"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/089198879600900101"},{"key":"e_1_3_1_39_2","unstructured":"Tracy JW Webster LT Jr. Drugs used in the chemotherapy of helminthiasis. In: Hardman JG Limbird LE Molinoff PB Gilman AG eds. Goodman and Gilman's the pharmacological basis of therapeutics 9th ed. New York: McGraw-Hill 1996:1009-1026."},{"key":"e_1_3_1_40_2","first-page":"5","volume":"26","year":"1987","unstructured":"Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharm 1987;26:521-530.","journal-title":"Neuropharm"},{"key":"e_1_3_1_41_2","first-page":"7","volume":"274","year":"1995","unstructured":"Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease. Selectively toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-770.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701023360101"},{"key":"e_1_3_1_43_2","first-page":"4","volume":"348","year":"1996","unstructured":"Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer disease. Lancet 1996;348:429-432.","journal-title":"Lancet"},{"key":"e_1_3_1_44_2","first-page":"4","volume":"47","year":"1996","unstructured":"McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996;47:425-432.","journal-title":"Neurology"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.50.5.1222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:22:01Z","timestamp":1711639321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.50.5.1222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1212\/WNL.50.5.1222"],"URL":"https:\/\/doi.org\/10.1212\/wnl.50.5.1222","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}